Abstract: The disclosure relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidases (Nox enzymes) and/or myeloperoxidase.
Type:
Grant
Filed:
May 5, 2016
Date of Patent:
August 14, 2018
Assignee:
Emory University
Inventors:
John David Lambeth, Thota Ganesh, Susan M. Smith, Aiming Sun
Abstract: The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
August 7, 2018
Assignee:
Emory University
Inventors:
Jianxiong Jiang, Thota Ganesh, Yuhong Du, Pahk Thepchatri, Yi Quan, Ray J. Dingledine
Abstract: This disclosure relates to methods of treating and diagnosing a tuberculosis infection as pulmonary active or latent based on biomarkers expressed on pools of CD4+ cells. In certain embodiments, the disclosure relates to methods of treatment of a subject diagnosed with tuberculosis comprising the steps of, measuring a pool of CD4 IFN-? cells for cells that also express CD38, HLA-DR, and/or Ki-67 providing a measurement; associating an increased measurement of CD4 IFN-? cells that also express CD38, HLA-DR, Ki-67, compared to a control, as an indication that the subject has active tuberculosis; and treating the subject with an aggressive tuberculosis treatment.
Type:
Grant
Filed:
May 5, 2015
Date of Patent:
August 7, 2018
Assignee:
Emory University
Inventors:
Jyothi Rengarajan, Toidi Adekambi, Christian C. Ibegbu
Abstract: This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis.
Type:
Grant
Filed:
September 23, 2014
Date of Patent:
July 31, 2018
Assignee:
Emory University
Inventors:
Brian P. Pollack, Richard W. Compans, Joanna A. Pulit-Penaloza, Ioanna Skountzou
Abstract: Embodiments of the disclosure encompass compositions and methods for generating immune responses in an animal or human host. Embodiments of the compositions encompass proteins derived from the surface proteins of bacteria and protozoa, and in particular the flagellum component flagellin, and which have adjunctival properties when administered in conjunction with an immunogen. Embodiments of the compositions of the disclosure are modified to incorporate a heterologous transmembrane-cytoplasmic domain allowing the peptides to be incorporated into virus-like particles. Embodiments of the methods of generating an immunological response in an animal or human comprise exposing the immune system of an animal or human host to an immunogen and a virus-like particle comprising an adjuvant polypeptide including a host cell Toll-like receptor ligand polypeptide having a transmembrane-cytoplasmic tail polypeptide, and a heterologous signal peptide.
Type:
Grant
Filed:
February 13, 2015
Date of Patent:
July 24, 2018
Assignees:
Emory University, Institute for Systems Biology
Inventors:
Richard L. Compans, Baozhong Wang, Jadranmka Boza, Ioanna Skountzou, Alan A. Aderem
Abstract: This disclosure relates to endothelial or endothelial like cells cultured from fibroblasts exposed to transcription factor ETV2. In certain embodiments, the disclosure relates to methods of producing endothelial or endothelial like cells comprising exposing fibroblasts with ETV2 under conditions such that the fibroblasts are modified to form a pool of cells expressing increased levels of endothelium surface markers compared to the fibroblasts. In certain embodiments, the disclosure relates to using endothelial like cells reported herein for the treatment of vascular, cardiac, and wound healing indications.
Type:
Grant
Filed:
April 29, 2015
Date of Patent:
July 17, 2018
Assignees:
Emory University, The Board of Trustees of the University of Illinois
Inventors:
Young-Sup Yoon, JiWoong Han, Sang Ho Lee, Changwon Park
Abstract: In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein.
Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.
Type:
Grant
Filed:
April 27, 2016
Date of Patent:
July 3, 2018
Assignees:
Cocrystal Pharma, Inc., Emory University
Inventors:
Steven J. Coats, Franck Amblard, Seema Mengshetti, Hao Li, Raymond F. Schinazi
Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
Type:
Grant
Filed:
May 18, 2016
Date of Patent:
June 19, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
June 12, 2018
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Wilbur A. Lam, Anton Sidorov, Zhigang Jlang
Abstract: This disclosure is in the area of research and therapeutics. In certain embodiments, it provides methods to assist in the purification of cell mixtures, e.g., cardiomyocytes, using molecular beacons targeting cell-type specific RNA, e.g. mRNA.
Type:
Grant
Filed:
September 22, 2016
Date of Patent:
June 12, 2018
Assignees:
Emory University, Georgia Tech Research Corporation
Inventors:
Young Sup Yoon, Gang Bao, Kiwon Ban, Brian Wile
Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
Type:
Application
Filed:
June 28, 2017
Publication date:
June 7, 2018
Applicants:
Emory University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
Inventors:
Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Type:
Grant
Filed:
March 12, 2012
Date of Patent:
June 5, 2018
Assignees:
Beth Israel Deaconess Medical Center, Inc., Emory University
Inventors:
Keith A. Reimann, Rijian Wang, Christian P. Larsen
Abstract: The disclosure relates to BH4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
Type:
Grant
Filed:
May 5, 2015
Date of Patent:
May 29, 2018
Assignees:
Emory University, The Board of Regents of the University of Texas System
Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
Abstract: This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
May 8, 2018
Assignees:
Emory University, Georgia Tech Research Corporation
Abstract: Methods, systems and computer-readable storage media relate to generating one or more consensus sequences. The methods may include determining a group of one or more reads with each main position without diversity from a group of one or more aligned reads based on diversity status of each main position, each group including sequence data disposed at a plurality of main positions and a plurality of secondary position regions disposed adjacent to the main positions. The methods may also include determining legitimate sequence data from each second position region having one or more nucleotides for each group of one or more reads without diversity; and generating a consensus sequence including sequence data disposed at each main position without diversity and legitimate sequence data disposed at each secondary position region for each group of one or more reads with each main position without diversity.
Type:
Application
Filed:
August 27, 2015
Publication date:
May 3, 2018
Applicant:
Emory University
Inventors:
Dario A. Dilernia, Jung-Ting Chien, Eric Hunter
Abstract: Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The VLP can also optionally include at least one adjuvant molecule expressed on the surface of the VLP.
Type:
Grant
Filed:
May 4, 2015
Date of Patent:
May 1, 2018
Assignee:
Emory University
Inventors:
Richard W. Compans, Chinglai Yang, Qizhi Yao, Sang-moo Kang
Abstract: Provided is a protein coded by a gene related to cell totipotency and a transcriptional activation domain of a mammalian YAP protein or a fusion protein of a segment with a transcriptional control activity, a coding nucleotide sequence, an expression vector and a composition thereof, as well as a method for inducing the pluripotent stem cells by using the fusion protein.
Type:
Grant
Filed:
June 17, 2014
Date of Patent:
April 17, 2018
Assignees:
Institute of Zoology, Chinese Academy of Sciences, Emory University School of Medicine
Inventors:
Dahua Chen, Peng Jin, Qinmiao Sun, Weiqi Tan
Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
Type:
Grant
Filed:
November 10, 2015
Date of Patent:
April 3, 2018
Assignees:
Cocrystal Pharma, LLC, Emory University
Inventors:
Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi